CORT — Corcept Therapeutics Incorporat
Is CORT overbought or oversold? Here is the current MarketMoodz read.
Corcept Therapeutics Incorporat (CORT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $70.07. The rating moved from Neutral to Oversold on November 13, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$70.07
- Last changeMoved from Neutral to Oversold on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Corcept Therapeutics Incorporat (CORT) is a specialty pharmaceutical company centered on cortisol modulation with existing commercial revenue and a pipeline that includes late‑stage assets. The combination of a revenue base, upcoming clinical catalysts, and potential partner interest supports upside potential, while limited disclosure and concentration of revenues increase execution risk. Recent market flows into defensive pharma and neutral social/SEC noise provide a supportive near‑term backdrop, but outcomes from clinical and regulatory events will be the primary drivers of the stock’s trajectory.
Key factors
- Niche therapeutic franchise focused on cortisol modulation with existing commercial product revenue that provides a base cash flow
- Late‑stage pipeline (relacorilant and other programs) with upcoming clinical readouts and potential label expansion that could materially re-rate the equity
- Favorable sector flows into defensive and pharma-related names supporting relative bid for healthcare small/mid caps in certain windows
- Potential for business development or partnering interest from larger pharma seeking specialty endocrinology/oncology assets
- Neutral-to-muted social and SEC filing sentiment with no large negative headlines in the recent window, reducing near‑term headline risk
Risks
- Clinical trial failure or disappointing efficacy/safety readouts for key pipeline candidates which would impair growth upside
- Heavy reliance on a small product portfolio or single-source revenue, making top-line vulnerable to competitive, pricing, or payor pressure
- Limited public disclosure in the provided data set (no fresh EDGAR comparisons), increasing uncertainty about cash runway and near‑term dilution risk
- Regulatory or reimbursement headwinds (including tighter Medicare/insurer scrutiny) that could constrain pricing and uptake
- Market volatility and low liquidity typical of specialty biotechs, which can amplify downside on negative news
See today's live rating, score and targets
Members see the live hourly rating for CORT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.